These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18704978)

  • 21. Beyond depression: citalopram for obsessive-compulsive disorder.
    Pato MT
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Obsessive-compulsive disorder].
    van Grootheest DS; van den Heuvel OA; Cath DC; van Oppen P; van Balkom AJ
    Ned Tijdschr Geneeskd; 2008 Oct; 152(43):2325-9. PubMed ID: 19024062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological approaches to treatment-resistant obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Barr LC; Aronson SC; Price LH
    J Clin Psychiatry; 1993 Jun; 54 Suppl():16-26. PubMed ID: 8331098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
    Korff S; Harvey BH
    Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
    Stein DJ; Andersen EW; Overo KF
    Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.
    Denys D
    Psychiatr Clin North Am; 2006 Jun; 29(2):553-84, xi. PubMed ID: 16650723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does melatonin mediate the therapeutic effects of 5-HT reuptake inhibitors in obsessive compulsive disorder?
    Sandyk R
    Int J Neurosci; 1992; 64(1-4):221-3. PubMed ID: 1342043
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in compulsive hoarding.
    Saxena S
    Curr Psychiatry Rep; 2008 Aug; 10(4):297-303. PubMed ID: 18627667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies.
    Jenike MA; Rauch SL
    J Clin Psychiatry; 1994 Mar; 55 Suppl():11-7. PubMed ID: 7915709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational neuroimaging research in pediatric obsessive-compulsive disorder.
    MacMaster FP
    Dialogues Clin Neurosci; 2010; 12(2):165-74. PubMed ID: 20623921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies.
    Barr LC; Goodman WK; Price LH; McDougle CJ; Charney DS
    J Clin Psychiatry; 1992 Apr; 53 Suppl():17-28. PubMed ID: 1532961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating obsessive-compulsive disorder. Options include medication, psychotherapy, surgery, and deep brain stimulation.
    Harv Ment Health Lett; 2009 Mar; 25(9):4-5. PubMed ID: 19368037
    [No Abstract]   [Full Text] [Related]  

  • 36. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent developments in neurobiology of obsessive-compulsive disorder.
    Jenike MA; Rauch SL; Cummings JL; Savage CR; Goodman WK
    J Clin Psychiatry; 1996 Oct; 57(10):492-503. PubMed ID: 8909341
    [No Abstract]   [Full Text] [Related]  

  • 39. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.
    Pallanti S; Hollander E; Goodman WK
    J Clin Psychiatry; 2004; 65 Suppl 14():6-10. PubMed ID: 15554782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.